A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies

Charles Blanke, Michael Stipanov, Jason Morrow, Mace Rothenberg, Rebecca Chinery, Yu Shyr, Robert Coffey, David H. Johnson, Steven D. Leach, R. Daniel Beauchamp

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Six patients with incurable malignancies were originally treated with vitamin E, 3200 IU/day for fourteen days, followed by the same dose of vitamin E daily plus LCV (20 mg/m2 iv bolus daily × 5) with 5FU (425 mg/m2 iv bolus immediately following LCV). The same schedule of LCV and 5FU was repeated 4 weeks later, then every 5 weeks indefinitely. When 3 of the first 6 had grade 3/4 toxicity, six more patients were treated on the identical drugs and schedule. Seven of twelve total patients had one or more grade 3/4 toxicities. Neutropenia, abdominal pain, and diarrhea were most common. No patient had a documented response, though seven patients did have stable disease. Though the combination of vitamin E and chemotherapy was toxic, this trial demonstrated maximal therapeutic doses of vitamin E can be combined with standard 5FU and LCV, without significantly increasing the side effects of the chemotherapy itself.

Original languageEnglish (US)
Pages (from-to)21-27
Number of pages7
JournalInvestigational New Drugs
Volume19
Issue number1
DOIs
StatePublished - 2001

Fingerprint

Leucovorin
Vitamin E
Fluorouracil
Neoplasms
Appointments and Schedules
Drug Therapy
Poisons
Neutropenia
Abdominal Pain
Diarrhea
Pharmaceutical Preparations

Keywords

  • Antioxidant
  • Chemotherapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Blanke, C., Stipanov, M., Morrow, J., Rothenberg, M., Chinery, R., Shyr, Y., ... Beauchamp, R. D. (2001). A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies. Investigational New Drugs, 19(1), 21-27. https://doi.org/10.1023/A:1006484031959

A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies. / Blanke, Charles; Stipanov, Michael; Morrow, Jason; Rothenberg, Mace; Chinery, Rebecca; Shyr, Yu; Coffey, Robert; Johnson, David H.; Leach, Steven D.; Beauchamp, R. Daniel.

In: Investigational New Drugs, Vol. 19, No. 1, 2001, p. 21-27.

Research output: Contribution to journalArticle

Blanke, C, Stipanov, M, Morrow, J, Rothenberg, M, Chinery, R, Shyr, Y, Coffey, R, Johnson, DH, Leach, SD & Beauchamp, RD 2001, 'A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies', Investigational New Drugs, vol. 19, no. 1, pp. 21-27. https://doi.org/10.1023/A:1006484031959
Blanke, Charles ; Stipanov, Michael ; Morrow, Jason ; Rothenberg, Mace ; Chinery, Rebecca ; Shyr, Yu ; Coffey, Robert ; Johnson, David H. ; Leach, Steven D. ; Beauchamp, R. Daniel. / A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies. In: Investigational New Drugs. 2001 ; Vol. 19, No. 1. pp. 21-27.
@article{d19c4d34d21e41c995a3fb994cf066a5,
title = "A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies",
abstract = "Six patients with incurable malignancies were originally treated with vitamin E, 3200 IU/day for fourteen days, followed by the same dose of vitamin E daily plus LCV (20 mg/m2 iv bolus daily × 5) with 5FU (425 mg/m2 iv bolus immediately following LCV). The same schedule of LCV and 5FU was repeated 4 weeks later, then every 5 weeks indefinitely. When 3 of the first 6 had grade 3/4 toxicity, six more patients were treated on the identical drugs and schedule. Seven of twelve total patients had one or more grade 3/4 toxicities. Neutropenia, abdominal pain, and diarrhea were most common. No patient had a documented response, though seven patients did have stable disease. Though the combination of vitamin E and chemotherapy was toxic, this trial demonstrated maximal therapeutic doses of vitamin E can be combined with standard 5FU and LCV, without significantly increasing the side effects of the chemotherapy itself.",
keywords = "Antioxidant, Chemotherapy",
author = "Charles Blanke and Michael Stipanov and Jason Morrow and Mace Rothenberg and Rebecca Chinery and Yu Shyr and Robert Coffey and Johnson, {David H.} and Leach, {Steven D.} and Beauchamp, {R. Daniel}",
year = "2001",
doi = "10.1023/A:1006484031959",
language = "English (US)",
volume = "19",
pages = "21--27",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies

AU - Blanke, Charles

AU - Stipanov, Michael

AU - Morrow, Jason

AU - Rothenberg, Mace

AU - Chinery, Rebecca

AU - Shyr, Yu

AU - Coffey, Robert

AU - Johnson, David H.

AU - Leach, Steven D.

AU - Beauchamp, R. Daniel

PY - 2001

Y1 - 2001

N2 - Six patients with incurable malignancies were originally treated with vitamin E, 3200 IU/day for fourteen days, followed by the same dose of vitamin E daily plus LCV (20 mg/m2 iv bolus daily × 5) with 5FU (425 mg/m2 iv bolus immediately following LCV). The same schedule of LCV and 5FU was repeated 4 weeks later, then every 5 weeks indefinitely. When 3 of the first 6 had grade 3/4 toxicity, six more patients were treated on the identical drugs and schedule. Seven of twelve total patients had one or more grade 3/4 toxicities. Neutropenia, abdominal pain, and diarrhea were most common. No patient had a documented response, though seven patients did have stable disease. Though the combination of vitamin E and chemotherapy was toxic, this trial demonstrated maximal therapeutic doses of vitamin E can be combined with standard 5FU and LCV, without significantly increasing the side effects of the chemotherapy itself.

AB - Six patients with incurable malignancies were originally treated with vitamin E, 3200 IU/day for fourteen days, followed by the same dose of vitamin E daily plus LCV (20 mg/m2 iv bolus daily × 5) with 5FU (425 mg/m2 iv bolus immediately following LCV). The same schedule of LCV and 5FU was repeated 4 weeks later, then every 5 weeks indefinitely. When 3 of the first 6 had grade 3/4 toxicity, six more patients were treated on the identical drugs and schedule. Seven of twelve total patients had one or more grade 3/4 toxicities. Neutropenia, abdominal pain, and diarrhea were most common. No patient had a documented response, though seven patients did have stable disease. Though the combination of vitamin E and chemotherapy was toxic, this trial demonstrated maximal therapeutic doses of vitamin E can be combined with standard 5FU and LCV, without significantly increasing the side effects of the chemotherapy itself.

KW - Antioxidant

KW - Chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0035094509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035094509&partnerID=8YFLogxK

U2 - 10.1023/A:1006484031959

DO - 10.1023/A:1006484031959

M3 - Article

C2 - 11291830

AN - SCOPUS:0035094509

VL - 19

SP - 21

EP - 27

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -